Handelsbanken Fonder
CRSP icon

Handelsbanken Fonder’s CRISPR Therapeutics CRSP Stock Holding History

Handelsbanken Fonder’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
35,000
+8,100
+30% +$427K 0.01% 828
2026
Q1 		$1.28M Hold
26,900
– – ﹤0.01% 934
2025
Q4 		$1.41M Buy
26,900
+3,000
+13% +$180K ﹤0.01% 889
2025
Q3 		$1.55M Hold
23,900
– – ﹤0.01% 826
2025
Q2 		$1.16M Hold
23,900
– – ﹤0.01% 895
2025
Q1 		$813K Sell
23,900
-500
-2% -$21.2K ﹤0.01% 1022
2024
Q4 		$960K Sell
24,400
-4,700
-16% -$222K ﹤0.01% 983
2024
Q3 		$1.37M Sell
29,100
-71,200
-71% -$3.61M 0.01% 812
2024
Q2 		$5.42M Buy
100,300
+83,600
+501% +$4.84M 0.02% 411
2024
Q1 		$1.14M Buy
16,700
+1,000
+6% +$71.6K ﹤0.01% 794
2023
Q4 		$983K Buy
15,700
+1,700
+12% +$94K ﹤0.01% 807
2023
Q3 		$635K Hold
14,000
– – ﹤0.01% 939
2023
Q2 		$786K Buy
14,000
+1,500
+12% +$85.1K ﹤0.01% 840
2023
Q1 		$565K Hold
12,500
– – ﹤0.01% 950
2022
Q4 		$508K Buy
12,500
+2,700
+28% +$143K ﹤0.01% 950
2022
Q3 		$640K Hold
9,800
– – ﹤0.01% 832
2022
Q2 		$596K Sell
9,800
-300
-3% -$17.6K ﹤0.01% 924
2022
Q1 		$634K Hold
10,100
– – ﹤0.01% 1034
2021
Q4 		$765K Hold
10,100
– – ﹤0.01% 1054
2021
Q3 		$1.13M Sell
10,100
-100
-1% -$12.6K 0.01% 840
2021
Q2 		$1.65M Buy
10,200
+1,300
+15% +$158K 0.01% 686
2021
Q1 		$1.08M Hold
8,900
– – 0.01% 800
2020
Q4 		$1.36M Sell
8,900
-2,400
-21% -$284K 0.01% 703
2020
Q3 		$945K Buy
11,300
+5,300
+88% +$470K 0.01% 745
2020
Q2 		$441K Buy
+6,000
New +$351K ﹤0.01% 1018

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Handelsbanken Fonder's CRSP Position: Q2 2026 in Review

Handelsbanken Fonder increased its CRISPR Therapeutics (CRSP) stake by 30% in Q2 2026, buying an estimated $427K and bringing the position to 35,000 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #828.

Handelsbanken Fonder first reported a position in CRSP in Q2 2020 and has held it in 25 quarters since. The position peaked at $5.42M in Q2 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Handelsbanken Fonder held 35,000 shares of CRISPR Therapeutics worth $1.91M as of Q2 2026.
  • Handelsbanken Fonder bought 8,100 CRISPR Therapeutics shares in Q2 2026, an estimated $427K.
  • CRISPR Therapeutics made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #828 holding.
  • Handelsbanken Fonder first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Handelsbanken Fonder's CRISPR Therapeutics position peaked at $5.42M in Q2 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.